thelancet.com
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials
Oral semaglutide was not efficacious in slowing clinical progression in participants
with early Alzheimer's disease. Safety and tolerability of semaglutide in early Alzheimer's
disease is consistent w...